4.3 Article

Quality assuring Plan of the day selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module

Journal

CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
Volume 19, Issue -, Pages 27-32

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ctro.2019.07.006

Keywords

IGRT; Adaptive; Bladder; Radiotherapy; Trial QA

Funding

  1. Cancer Research UK [CRUK/12/055]
  2. Cancer Research UK (CRUK) core grant [C1491/A15955]

Ask authors/readers for more resources

Background and purpose: Hypofractionated bladder RT with or without image guided adaptive planning (HYBRID) is a multicentre clinical trial investigating Plan of the Day (PoD) adaptive radiotherapy for bladder cancer. To ensure correct PoD selection a pre-accrual guidance and assessment module was developed as part of an image guided radiotherapy quality assurance (IGRT QA) credentialing programme. This study aimed to evaluate its feasibility and effectiveness across multiple recruiting centres. Materials and methods: Individuals from participating centres remotely accessed an image database in order to complete the PoD module. An assessment score of >= 83% was required in order to receive QA approval. A questionnaire was used to gather user feedback on the module. PoD decisions for the first patient at each recruiting centre were retrospectively reviewed for protocol adherence. Results: 71 radiation therapists (RTTs) from 10 centres completed the PoD module. The median assessment score was 92% (Range: 58-100%) with 79% of RTTs passing the assessment on first attempt. All questionnaire respondents reported that the PoD module prepared them for plan selection. In 51/60 of on-trial treatments reviewed, the PoD selected by the centre agreed with QA reviewers. Conclusions: The PoD QA module was successfully implemented in a multicentre trial and enabled pre-accrual assessment of protocol understanding. This increased operator confidence and resulted in appropriate PoD selection on-trial. Crown Copyright (C) 2019 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available